Short Link N promotes disc repair in a rabbit model of disc degeneration
Arthritis Research & Therapy volume 20, Article number: 201 (2018)
The degeneration of the intervertebral disc (IVD) is characterized by proteolytic degradation of the extracellular matrix, and its repair requires the production of an extracellular matrix with a high proteoglycan-to-collagen ratio characteristic of a nucleus pulposus (NP)-like phenotype in vivo. At the moment, there is no medical treatment to reverse or even retard disc degeneration. The purpose of the present study was to determine if a low dose of short link N (sLN), a recently discovered fragment of the link N peptide, could behave in a manner similar to that of link N in restoring the proteoglycan content and proteoglycan-to-collagen ratio of the disc in a rabbit model of IVD degeneration, as an indication of its potential therapeutic benefit in reversing disc degeneration.
Adolescent New Zealand white rabbits received an annular puncture with an 18-gauge needle into two noncontiguous discs to induce disc degeneration. Two weeks later, either saline (10 μL) or sLN (25 μg in 10 μL saline) was injected into the center of the NP. The sLN concentration was empirically chosen at a lower molar concentration equivalent to half that of link N (100 μg in 10 μL). The effect on radiographic, biochemical and histologic changes were evaluated.
Following needle puncture, disc height decreased by about 25–30% within 2 weeks and maintained this loss for the duration of the 12-week study; a single 25-μg sLN injection at 2 weeks partially restored this loss in disc height. sLN injection led to an increase in glycosaminoglycans (GAG) content 12 weeks post-injection in both the NP and annulus fibrosus (AF). There was a trend towards maintaining control disc collagen-content with sLN supplementation and the GAG-to-collagen ratio in the NP was increased when compared to the saline group.
When administered to the degenerative disc in vivo, sLN injection leads to an increase in proteoglycan content and a trend towards maintaining control disc collagen content in both the NP and AF. This is similar to link N when it is administered to the degenerative disc. Thus, pharmacologically, sLN supplementation could be a novel therapeutic approach for treating disc degeneration.
Adjacent vertebrae are linked together by the fibrocartilaginous intervertebral discs (IVDs), which endow the spine with its flexibility and resistance to compression . IVDs are composed of highly organized concentric fiber-reinforced lamellae layers rich in collagen termed the annulus fibrosus (AF), and a central gel-like and pressurized nucleus pulposus (NP) consisting mainly of randomly oriented collagen fibrils and high concentrations of the proteoglycan aggrecan [2, 3]. The ability to withstand compression is provided by the high negative-charge density of the glycosaminoglycan (GAG) chains attached to aggrecan monomers [4, 5]. In the human, the IVDs are separated from the vertebral bone by the cartilage endplates at the superior and inferior boundaries, which are a major pathway of nutrient supply into the IVD [6, 7]. These substructures provide the disc’s mechanical function to support and distribute large and multi-directional spine loads and deformations.
One of the factors that lead to degeneration of the IVD is a reduction in nutrient supply. Calcification of the endplate has been considered to play a significant role as a barrier to nutrient transport into the IVD. Furthermore, the functional ability of the IVD is impaired due to decreases in GAG content, which occurs relatively early during human aging [8, 9]. During IVD degeneration, dramatic changes occur in the NP as it becomes more fibrous and loses the delineation between the NP and the inner AF [3, 10]. At later stages of degeneration, the collagen fibrils of the NP become damaged, leading to the formation of clefts that eventually also affect the AF. This degeneration of IVD structure and function is a progressive condition and presents a major socioeconomic burden worldwide because of its strong association with back pain. The most recent Global Burden of Disease study identified back pain as the single most common cause of disability worldwide . Other contributors to disc degeneration are biochemical [12,13,14,15,16], biomechanical [17,18,19,20] and genetic [21,22,23,24]. Historically, disc degeneration has been assumed to be the result of aging and “wear and tear” from mechanical insults and injuries. However, the Twin Spine Study has recently suggested that IVD degeneration may be due, in large part, to genetically determined “developmental” changes in disc structure .
Spinal fusion surgery is a commonly performed surgical procedure for the treatment of degenerative disc disease (DDD) with severe pain . While this may provide symptomatic relief, studies have demonstrated that spinal fusion surgery accelerates disc degeneration in adjacent vertebral segments . Ideally, biological repair of the degenerating IVD would be preferable to fusion, though at present there are no disease-modifying medications yet available.
Link N is a naturally occurring 16 amino acid peptide representing the N terminal region of link protein, a glycoprotein that stabilizes proteoglycan aggregates in IVD and cartilage by binding to both hyaluronic acid and aggrecan . The peptide is generated by matrix metalloproteinases (MMPs) during tissue turnover in vivo  and has been shown to enhance proteoglycan synthesis by IVD cells and intact human discs, and also to increase disc height in a rabbit disc puncture degeneration model . It is postulated that these biochemical changes are due to link N interacting with the BMP type II receptor on disc cells and activating intracellular Smad1/5 signaling . Hence, link N may provide therapeutic benefit to degenerating discs. Two major advantages of link N over recombinant growth factors are that it is more economically viable and does not stimulate bone formation . Recently, we found that the first 1–8 residues of link N (short link N, sLN) are responsible for the biological activity .
The purpose of the present study was to determine whether a low dose of sLN could promote disc repair by assessing proteoglycan content and the proteoglycan-to-collagen ratio in a rabbit model of IVD degeneration.
Short link N (sLN) DHLSDNYT (link N 1–8) with a mass of 964 Da was synthesized by CanPeptide (Pointe Claire, QC, Canada).
Surgical procedure for the rabbit IVD degeneration model
Twenty New Zealand White rabbits (specific pathogen-free (SPF), 4–6 month-old skeletally mature rabbits, Western Oregon Rabbit Co. OR, USA) weighing approximately 3.5 kg were used in the present study (Fig. 1) with the approval of the Institutional Animal Care and Use Committee, La Jolla, CA, USA. Five days before surgery, a pre-operative x-ray was taken as a baseline control under anesthesia by the intramuscular administration of ketamine hydrochloride (25 mg/kg) and acepromazine maleate (1 mg/kg, 10 mg/mL). IVD degeneration was induced in all rabbits as previously described . Briefly, the rabbits were placed in a lateral prone position and the anterior surfaces of three consecutive lumbar IVDs (L2/3, L3/4 and L4/5) were exposed through a posterolateral retroperitoneal approach by blunt dissection of the psoas muscle. IVD degeneration was induced at the L2/3 and L4/5 levels, by AF puncture in the ventral aspect into the NP using an 18G needle with a stopper device that allows the needle to penetrate to a maximum depth of 5 mm. The IVD at the level L3/4 was left intact and used as a non-punctured control. The surgical wound was repaired in layers and the skin was closed using staples. Intraoperative and postoperative x-rays were taken to confirm the level of puncture. After recovery from anesthesia, the rabbits were returned to their cages and mobilized ad libitum. The x-rays confirmed the presence of degenerated discs, 2 weeks post-surgery.
Two weeks after the initial surgery, both punctured discs (L2/3 and L4/5) of each rabbit were injected intradiscally through their anterolateral surfaces into the NP area with either saline (10 μL/disc) or 25 μg sLN dissolved in 10 μL saline as indicated in Table 1, using a MS*GFN25 microsyringe equipped with a XX*MS16 needle (Ito Corporation, Fuji, Japan) (Fig. 1). In our previous study with full length link N, we used 100 μg per disc . The non-punctured disc (level L3/4) of each rabbit remained untreated and was used as an internal control for IVD repair assessment. After intradiscal injection, the rabbits were returned to their cages and closely monitored for behavior, appetite and change in body weight.
Radiographic analysis of IVD height
Radiographs were taken of all rabbit spines in a flexed position, using a digital radiography system (resolution 71 μm; NAOMI, Nagano, Japan) at biweekly intervals up to 12 weeks after disc puncture (Fig. 1). A consistent level of anesthesia (ketamine hydrochloride 25 mg/kg and acepromazine maleate 1 mg/kg) was maintained during radiography of each animal and at each time point to obtain a similar degree of muscle relaxation, which may affect the disc height. To decrease the error from axial rotation of the spine and from beam divergence, radiographs were repeated until a complete lateral image was obtained on each animal in the lateral decubitus position with the beam centered at 4 cm from the rabbit iliac crest. An orthopedic researcher who was blinded to the study group, surgical procedure and time point independently interpreted all x-ray images. All radiograph images were analyzed using a custom program for MATLAB software (Natick, MA, USA).
IVD height, expressed as the disc height index (DHI = IVD height/adjacent vertebral body height), was based on the previously developed method . The mean DHI was calculated by averaging the height measurements obtained from the anterior, middle and posterior portions of the IVD and dividing that by the average of the adjacent vertebral body heights. Changes in the DHI of injected discs were expressed as percentage DHI (%DHI) and normalized to the measured non-punctured control DHI (normalized %DHI = [punctured DHI/non-punctured DHI] × 100). The preoperative x-ray was always used as a baseline measurement: %DHI = (postoperative DHI/preoperative DHI) × 100.
Euthanasia and sample preparation
At 12 weeks after treatment, rabbits in each group were anesthetized with ketamine hydrochloride (25 mg/kg) and acepromazine maleate (1 mg/kg) and euthanatized with an excess dose of pentobarbital (Euthanasia B solution: Henry Schein Inc., Melville, NY, USA). Rabbit discs were excised from spines and either prepared for histological evaluation or dissected into NP and AF tissues for biochemical analysis (Table 1).
Histological assessment of the IVD
Rabbit IVDs containing part of the vertebrae were fixed in 10% neutralized formalin, decalcified with Cal-Ex™ II Fixative/Decalcifier and embedded in paraffin. Sagittal 4-μm sections of each IVD were dewaxed in Safeclear™ Tissue Clearing Agent (ThermoFisher Scientific, USA) and stepwise rehydrated in ethanol: 100%, 95%, 70%, 50%, distilled water. For proteoglycan content, the sections were stained with 1% Alcian blue 8GX (pH 1.0) for 30 min and then counterstained in 0.1% Nuclear Fast red for 5 min. Sections were dehydrated and mounted in Permount (ThermoFisher Scientific, USA). Images were captured on a Leica DM LB2 light microscope (Leica Microsystems GmbH, Wetzlar, Germany).
Treated discs from each experimental group were removed from each lumbar spine for biochemical analysis (Table 1). Discs from six additional control rabbits were also analyzed. After disc excision, the NP was separated from the AF. All specimens were weighed (wet weight) and digested with proteinase K at 56 °C for 48 h. The proteinase K tissue digests were quantified for sulfated glycosaminoglycans (GAG) and total collagen content.
Sulfated glycosaminoglycans (GAGs) were quantified in tissue extracts by a modified dimethyl methylene blue (DMMB) dye-binding assay [34, 35]. Samples were diluted to fall within the middle of the linear range of the standard curve. Extraction buffer of an equal volume to the tissue extracts was added to the standard curve to compensate for possible interference.
The proteinase K tissue digests were used for analysis of hydroxyproline as a measure of total collagen content. For analysis, digests were first hydrolyzed in 6 M HCl to release free hydroxyproline, which was then quantitated using dimethylaminobenzaldehyde . Total collagen content was estimated assuming that hydroxyproline content is equivalent to 10% of the weight of each collagen α chain .
Statistical analysis was performed using the GraphPad Prism (version 6.03; GraphPad Software, Inc., La Jolla, CA, USA) program. Differences between the sLN-injected and saline-injected groups were assessed with one or two-way repeated analysis of variance (ANOVA) and post hoc Tukey’s multiple comparisons test.
Following needle puncture, the normalized %DHI decreased by about 25–30% over the next 2 weeks compared with the baseline DHI values obtained before puncture. This loss stabilized and there was no recovery over the 12-week period (Fig. 2). A single 25-μg sLN injection appeared to begin reversing the loss of disc height during the first 2 weeks, and by week 4 the mean normalized %DHI of injected discs in the sLN group was statistically higher than that in the saline group. This difference was maintained during the next 8 weeks with the mean normalized %DHI of injected discs in the sLN group being significantly higher than that in the saline group at 12 weeks after the sLN 25-μg injection.
GAG concentration was measured in the discs because of the major role proteoglycans play in the functional ability of IVDs to swell and resist compressive forces . There was a significant decrease in GAG content in the NP and AF of discs from the saline group when compared to the non-punctured discs after 12 weeks, indicative of proteoglycan (aggrecan) loss (Fig. 3). sLN stimulated an increase in GAG content in both the NP and AF.
Alcian blue was used to stain sections of the disc for histological analysis in order to study proteoglycan content and distribution in the NP (Fig. 4). The blue color intensity decreased in the NP of punctured discs (saline-treated) when compared to the non-punctured control. In contrast, sLN supplementation led to an increase in the intensity of the blue color, which was distributed uniformly throughout the NP. The Alcian blue staining in the sLN-treated disc was comparable to non-punctured discs confirming increased proteoglycan content and uniform distribution throughout the NP. However, reduced Alcian blue staining does not indicate absence of proteoglycan in the tissue but rather a reduced content.
Hydroxyproline as an indicator of disc collagen content was measured because of the intimate role that collagen plays in the mechanical strength of IVDs and its resistance to swelling. The discs responded to AF puncture by significantly increasing collagen content in both the NP and AF when compared to the non-punctured discs (p < 0.01 in the NP; p < 0.001 in the AF) (Fig. 5). Treatment with sLN maintained collagen content in both NP and AF tissues to levels comparable to non-punctured discs.
We have previously shown that an extracellular matrix with a high proteoglycan-to-collagen ratio can be used as a means to identify a NP-like phenotype in vivo . In non-punctured discs with no degeneration, the GAG-to-collagen ratio in the NP was on average 10.5:1, while that of the AF was 1.0:1 (Fig. 6). Following needle puncture, the GAG-to-collagen ratios in the NP and AF decreased significantly to an average of 0.9:1 and 0.4:1, respectively. For the sLN treated groups, the GAG-to-collagen ratio in the NP increased when compared to the saline group to an average of 3.0:1 while that of the AF was increased to 0.9:1.
Previous studies have shown that link N can stimulate the proteoglycan content and increase disc height when administered to the degenerative rabbit disc in vivo  . The present data indicate that sLN is as good as link N in stimulating the proteoglycan content in this model at half the molar mass. The changes in proteoglycan and disc height shown here with sLN are also similar to those observed with bone morphogenetic protein 7 (BMP7) . The increase in disc height observed was not linear. There seems to be a plateau effect in about 6–8 weeks. It is unclear whether this is of any significance in the repair process or just reflects the natural variation in disc height measurements.
Injection of several growth factors, such as BMP-7, transforming growth factor-β (TGFβ), fibroblast growth factor (bFGF), growth/differentiation factor 5 (GDF-5) into the disc has been widely studied as a means to stimulate extracellular matrix production and cell proliferation [39,40,41,42]. Intradiscal administration of recombinant human BMP-7 in a rabbit model of disc degeneration led to an increased disc height and enhanced proteoglycan content of the NP [39, 42], showing its potential to promote repair in disc degeneration. However, others have found extensive extradiscal bone formation in a spontaneous canine IVD degeneration model treated with BMP-7 . Thus sLN appears to be as effective as other growth factors in stimulating repair of the IVD in vivo, but in common with link N does not induce bone formation . A second major advantage of sLN over a growth factor such as BMP-7 for therapeutic use is that is simple and cost-effective to manufacture.
In the present work, we wanted to see if sLN would perform the same as link N in terms of in disc repair. We used a molar concentration (25 μg) half of that used previously with long link N to determine whether lower doses can improve disc repair. Without sLN treatment there was a significant decrease in GAG content in the NP and AF with loss of disc height, indicative of proteoglycan degradation and loss. After sLN treatment there was both an increase in disc height and an increase in GAG concentration, indicative of new proteoglycan synthesis in both the NP and AF.
In contrast, a significant increase in collagen content was observed throughout the disc during degeneration in the absence of sLN. This can be explained in part by the decrease in disc volume due to compression. However, as disc height decreases by 25%, it is likely that new collagen synthesis must also be occurring. With a 25-μg sLN injection, the collagen content decreases relative to degeneration alone, which could be due partly to re-swelling and partly to diminished synthesis. Since collagen is initially deposited during the 2-week degeneration period, some collagen may remain in the NP even following sLN treatment due to its slow removal during tissue remodeling.
The present histological evaluation using Alcian blue staining indicates that the non-punctured NP matrix and that treated with sLN is Alcian blue positive. It was reported that in a relatively non-degenerated human Pfirrmann grade-2 disc, the NP matrix is uniformly positive for Alcian blue . In a mildly degenerated Pfirrmann grade-3 disc and in a more degenerated Pfirrmann grade-4 disc, the NP matrix is more fibrous and the Alcian blue reactivity is significantly reduced, suggesting that degeneration is associated with an alteration in proteoglycan content. The increase in Alcian blue staining with sLN is consistent with increased proteoglycan content and disc height, suggesting that sLN mitigates further degeneration and stimulates repair. Interestingly, although NP cellularity is initially affected following induced degeneration in our puncture model, cellularity was preserved following sLN treatment unlike the saline controls as observed from our histological sections. In the absence of sLN, cellularity appeared to diminish as the degeneration cascade was allowed to progress; in the presence of sLN, cellularity was maintained, due to the inhibition of cell death.
In conclusion, sLN injection can stimulate proteoglycan production in vivo in both the NP and AF similar to link N when it is administered to the degenerative disc. Thus, pharmacologically sLN supplementation could be a potential therapeutic approach for treating disc degeneration.
Bone morphogenic protein
Degenerative disc disease
Disc height index
Short link N
Benjamin M, Evans EJ. Fibrocartilage. J Anat. 1990;171:1–15.
Mwale F. Collagen and other proteins of the nucleus pulposus, annulus fibrosus, and cartilage endplates. IM Shapiro, MV Risbud (eds). The Intervertebral discs. 2013;5:79–92.
Roughley PJ. Biology of intervertebral disc aging and degeneration: involvement of the extracellular matrix. Spine (Phila Pa 1976). 2004;29(23):2691–9.
Oegema TR Jr. Biochemistry of the intervertebral disc. Clin Sports Med. 1993;12(3):419–39.
Watanabe H, Yamada Y, Kimata K. Roles of aggrecan, a large chondroitin sulfate proteoglycan, in cartilage structure and function. J Biochem. 1998;124(4):687–93.
Urban JP, Smith S, Fairbank JC. Nutrition of the intervertebral disc. Spine (Phila Pa 1976). 2004;29(23):2700–9.
Grant M, Epure LM, Salem O, AlGarni N, Ciobanu O, Alaqeel M, Antoniou J, Mwale F. Development of a large animal long-term intervertebral disc organ culture model that includes the bony vertebrae for ex vivo studies. Tissue Eng Part C Methods. 2016;22(7):636–43.
Antoniou J, Steffen T, Nelson F, Winterbottom N, Hollander AP, Poole RA, Aebi M, Alini M. The human lumbar intervertebral disc: evidence for changes in the biosynthesis and denaturation of the extracellular matrix with growth, maturation, ageing, and degeneration. J Clin Invest. 1996;98(4):996–1003.
Mwale F, Roughley P, Antoniou J. Distinction between the extracellular matrix of the nucleus pulposus and hyaline cartilage: a requisite for tissue engineering of intervertebral disc. Eur Cell Mater. 2004;8:58–63. discussion -4
An HS, Anderson PA, Haughton VM, Iatridis JC, Kang JD, Lotz JC, Natarajan RN, Oegema TR Jr, Roughley P, Setton LA, et al. Introduction: disc degeneration: summary. Spine (Phila Pa 1976). 2004;29(23):2677–8.
Hoy D, March L, Brooks P, Blyth F, Woolf A, Bain C, Williams G, Smith E, Vos T, Barendregt J, et al. The global burden of low back pain: estimates from the Global Burden of Disease 2010 study. Ann Rheum Dis. 2014;73(6):968–74.
Kang JD, Stefanovic-Racic M, McIntyre LA, Georgescu HI, Evans CH. Toward a biochemical understanding of human intervertebral disc degeneration and herniation. Contributions of nitric oxide, interleukins, prostaglandin E2, and matrix metalloproteinases. Spine (Phila Pa 1976). 1997;22(10):1065–73.
Goupille P, Jayson MI, Valat JP, Freemont AJ. Matrix metalloproteinases: the clue to intervertebral disc degeneration? Spine (Phila Pa 1976). 1998;23(14):1612–26.
Oegema TR Jr, Johnson SL, Aguiar DJ, Ogilvie JW. Fibronectin and its fragments increase with degeneration in the human intervertebral disc. Spine. 2000;25(21):2742–7.
Roberts S, Caterson B, Menage J, Evans EH, Jaffray DC, Eisenstein SM. Matrix metalloproteinases and aggrecanase: their role in disorders of the human intervertebral disc. Spine (Phila Pa 1976). 2000;25(23):3005–13.
Akhatib B, Onnerfjord P, Gawri R, Ouellet J, Jarzem P, Heinegard D, Mort J, Roughley P, Haglund L. Chondroadherin fragmentation mediated by the protease HTRA1 distinguishes human intervertebral disc degeneration from normal aging. J Biol Chem. 2013;288(26):19280–7.
Ishihara H, McNally DS, Urban JP, Hall AC. Effects of hydrostatic pressure on matrix synthesis in different regions of the intervertebral disk. J Appl Physiol (1985). 1996;80(3):839–46.
Handa T, Ishihara H, Ohshima H, Osada R, Tsuji H, Obata K. Effects of hydrostatic pressure on matrix synthesis and matrix metalloproteinase production in the human lumbar intervertebral disc. Spine (Phila Pa 1976). 1997;22(10):1085–91.
Hutton WC, Elmer WA, Boden SD, Hyon S, Toribatake Y, Tomita K, Hair GA. The effect of hydrostatic pressure on intervertebral disc metabolism. Spine (Phila Pa 1976). 1999;24(15):1507–15.
Hsieh AH, Lotz JC. Prolonged spinal loading induces matrix metalloproteinase-2 activation in intervertebral discs. Spine (Phila Pa 1976). 2003;28(16):1781–8.
Annunen S, Paassilta P, Lohiniva J, Perala M, Pihlajamaa T, Karppinen J, Tervonen O, Kroger H, Lahde S, Vanharanta H, et al. An allele of COL9A2 associated with intervertebral disc disease. Science. 1999;285(5426):409–12.
Kawaguchi Y, Osada R, Kanamori M, Ishihara H, Ohmori K, Matsui H, Kimura T. Association between an aggrecan gene polymorphism and lumbar disc degeneration. Spine. 1999;24(23):2456–60.
Ala-Kokko L. Genetic risk factors for lumbar disc disease. Ann Med. 2002;34(1):42–7.
Roughley P, Martens D, Rantakokko J, Alini M, Mwale F, Antoniou J. The involvement of aggrecan polymorphism in degeneration of human intervertebral disc and articular cartilage. Eur Cell Mater. 2006;11:1–7.
Battie MC, Videman T, Kaprio J, Gibbons LE, Gill K, Manninen H, Saarela J, Peltonen L. The Twin Spine Study: contributions to a changing view of disc degeneration. Spine J. 2009;9(1):47–59.
Rajaee SS, Bae HW, Kanim LE, Delamarter RB. Spinal fusion in the United States: analysis of trends from 1998 to 2008. Spine (Phila Pa 1976). 2012;37(1):67–76.
Levin DA, Hale JJ, Bendo JA. Adjacent segment degeneration following spinal fusion for degenerative disc disease. Bull NYU Hosp Jt Dis. 2007;65(1):29–36.
Melching LI, Roughley PJ. The role of link protein in mediating the interaction between hyaluronic acid and newly secreted proteoglycan subunits from adult human articular cartilage. J Biol Chem. 1985;260(30):16279–85.
Donohue PJ, Jahnke MR, Blaha JD, Caterson B. Characterization of link protein(s) from human intervertebral-disc tissues. The Biochemical journal. 1988;251(3):739–47.
Mwale F, Masuda K, Pichika R, Epure LM, Yoshikawa T, Hemmad A, Roughley PJ, Antoniou J. The efficacy of Link N as a mediator of repair in a rabbit model of intervertebral disc degeneration. Arthritis Res Ther. 2011;13(4):R120.
Wang Z, Weitzmann MN, Sangadala S, Hutton WC, Yoon ST. Link protein N-terminal peptide binds to bone morphogenetic protein (BMP) type II receptor and drives matrix protein expression in rabbit intervertebral disc cells. J Biol Chem. 2013;288(39):28243–53.
Gawri R, Ouellet J, Onnerfjord P, Alkhatib B, Steffen T, Heinegard D, Roughley P, Antoniou J, Mwale F, Haglund L. Link N is cleaved by human annulus fibrosus cells generating a fragment with retained biological activity. J Orthop Res. 2014;32(9):1189–97.
Masuda K, Aota Y, Muehleman C, Imai Y, Okuma M, Thonar EJ, Andersson GB, An HS. A novel rabbit model of mild, reproducible disc degeneration by an anulus needle puncture: correlation between the degree of disc injury and radiological and histological appearances of disc degeneration. Spine (Phila Pa 1976). 2005;30(1):5–14.
Barbosa I, Garcia S, Barbier-Chassefiere V, Caruelle JP, Martelly I, Papy-Garcia D. Improved and simple micro assay for sulfated glycosaminoglycans quantification in biological extracts and its use in skin and muscle tissue studies. Glycobiology. 2003;13(9):647–53.
Mort JS, Roughley PJ. Measurement of glycosaminoglycan release from cartilage explants. Methods Mol Med. 2007;135:201–9.
Burleigh MC, Barrett AJ, Lazarus GS. Cathepsin B1. A lysosomal enzyme that degrades native collagen. Biochem J. 1974;137(2):387–98.
Nimni ME. Collagen: structure, function, and metabolism in normal and fibrotic tissues. Semin Arthritis Rheum. 1983;13(1):1–86.
Urban JP, Roberts S. Development and degeneration of the intervertebral discs. Mol Med Today. 1995;1(7):329–35.
Masuda K, Imai Y, Okuma M, Muehleman C, Nakagawa K, Akeda K, Thonar E, Andersson G, An HS. Osteogenic protein-1 injection into a degenerated disc induces the restoration of disc height and structural changes in the rabbit anular puncture model. Spine (Phila Pa 1976). 2006;31(7):742–54.
Masuda K. Biological repair of the degenerated intervertebral disc by the injection of growth factors. Eur Spine J. 2008;17(Suppl 4):441–51.
Walsh AJ, Bradford DS, Lotz JC. In vivo growth factor treatment of degenerated intervertebral discs. Spine (Phila Pa 1976). 2004;29(2):156–63.
An HS, Takegami K, Kamada H, Nguyen CM, Thonar EJ, Singh K, Andersson GB, Masuda K. Intradiscal administration of osteogenic protein-1 increases intervertebral disc height and proteoglycan content in the nucleus pulposus in normal adolescent rabbits. Spine (Phila Pa 1976). 2005;30(1):25–31. discussion -2
Willems N, Bach FC, Plomp SG, van Rijen MH, Wolfswinkel J, Grinwis GC, Bos C, Strijkers GJ, Dhert WJ, Meij BP, et al. Intradiscal application of rhBMP-7 does not induce regeneration in a canine model of spontaneous intervertebral disc degeneration. Arthritis Res Ther. 2015;17:137.
Mwale F, Wang HT, Roughley P, Antoniou J, Haglund L. Link N and mesenchymal stem cells can induce regeneration of the early degenerate intervertebral disc. Tissue Eng Part A. 2014;20(21–22):2942–9.
Antoniou J, Epure LM, Michalek AJ, Grant MP, Iatridis JC, Mwale F. Analysis of quantitative magnetic resonance imaging and biomechanical parameters on human discs with different grades of degeneration. J Magn Reson Imaging. 2013;38(6):1402–14.
We thank Allan Mandelzys for his helpful comments and Trepso Therapeutics Inc. for providing short Link N. This work was supported by the Canadian Institute of Health Research.
This work was supported by the Canadian Institutes of Health Research.
Availability of data and materials
Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.
The animal studies were approved by the University of California San Diego Institutional Animal Care and Use Committee, La Jolla, CA, USA.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Mwale, F., Masuda, K., Grant, M.P. et al. Short Link N promotes disc repair in a rabbit model of disc degeneration. Arthritis Res Ther 20, 201 (2018). https://doi.org/10.1186/s13075-018-1625-9
- Intervertebral disc degeneration
- Tissue engineering
- Bioactive peptides
- Short link N